Olivia Vizier

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in areas such as oncology and autoimmunity.

Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner Summary: SO-C101 is a IL-15 superagonist being developed for the treatment of advanced solid tumors – currently in an ongoing Phase

When it comes to fighting COVID-19, doctors say your body’s immune response can often time be worse than the symptoms of the disease itself. “Unfortunately, this COVID-19 generates a hyper-immune response. The immune response is actually maladaptive to and that actually causes its own dama

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity.

Roche and Immunomedics have expanded their checkpoint inhibitor-ADC partnership from TNBC to include other solid tumours: UC and NSCLC. What promise does combining ADC Trodelvy and checkpoint inhibitor Tecentriq have in overcoming unmet needs in these cancer types?

Many human diseases are driven by the dysfunction or dysregulation of proteins. However, up to 80% of proteins do not possess binding sites suitable for direct binding of small molecule drugs, making them “undruggable”. To overcome this problem, Anima Biotech has developed their Translation Control Therapeutics platform to identify drugs with the ability to interfere

A novel immune-based, gene therapy approach is entering phase 2 trials (ClinicalTrials.gov Identifier: NCT04006119) for glioblastoma multiforme (GBM) after promising preliminary safety and efficacy data. Despite encouraging results in several tumor types such as melanoma, colorectal, and lung, immunotherapies have yet to show any significant benefit in patients with brain tumors. The new technique by Ziopharm

A Phase 1/2 clinical trial assessing Arrowhead Pharmaceuticals‘ investigational inhaled therapy, ARO-ENaC, for the treatment of cystic fibrosis (CF), has dosed its first participants, the company announced.

Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising. GIGA-2050, a new class of drug called a recombinant hyperimmune, offers 100-fold higher potency than convalescent serum therapy.

To support Valneva’s Covid-19 vaccine VLA2001, the UK Government has agreed to make a joint investment into the company’s Scottish manufacturing facility. Valneva chief financial officer David Lawrence notes how large a vote of confidence this in the company’s vaccine expertise.

Rather than rest in success, Dr. Chang took a keen interest in Ansun Biopharma, a company founded in 2003 by virologists and molecular biologists pursuing a novel approach to treat otherwise untreatable viral flu strains. Ansun’s founding intentions were true, its science was solid, and in those early days, its funding was secure. In fact,

In December, Rocket Pharma presented results from a Phase I trial on RP-L102, a gene therapy for Fanconi anemia. Unlike earlier trials, these new results were from patients treated with a commercial-grade version of the product.

Cidara Therapeutics’ lead drug, rezafungin, now in Phase 3 development, is a broad-spectrum antifungal in a known class, the echinocandins, but the COVID-19 pandemic has moved the spotlight to the antiviral Fc-conjugate (AVC) drugs in the company’s novel antiviral platform that offer both prevention and treatment. Its AVCs are designed to attack viruses directly and

While Immunomedics CMO Loretta Itri, M.D. is no stranger to taking drugs across the commercial finish line in big pharma environments, her most recent win with TRODELVY was very, very different. On this episode, Dr. Itri shares insight on her small biopharma’s first commercial launch, the manufacturing and regulatory approval challenges that were overcome to

The problem of drug resistance isn’t limited to bacteria. It is also a growing concern with fungal species that is causing an increasing need for new agents to combat these microbes. Scynexis is developing the experimental therapy ibrexafungerp, the first of a new class of therapies for serious fungal infections. We spoke to Marco Taglietti,

The options that clinicians currently have to treat patients with systemic fungal infections are limited. “Because they’re eukaryotes, many of the potentially available targets that are essential for growth or reproduction in fungi resemble the [equivalent] target in humans, and so are really not available as a drug target,” explained Jeffrey Stein, CEO of US-based antifungal developer

Speciality vaccine biotech Valneva outlines seroconversion rates and safety of candidate Lyme disease vaccine that it is co-developing with partner Pfizer.

Antimicrobial resistance is a looming threat for modern medicine, but Australian biotech Recce Pharmaceuticals might have found a solution in its broad-spectrum synthetic antibiotic. Chloe Kent speaks to Recce executive director of regulatory affairs Michele Dilizia about the idea behind this novel approach.

Investors have boosted biotech startup Cerevance Inc.’s Series B financing to $65 million, powering its search for new approaches to battling neurological diseases. Cerevance, based in Boston, set out in January to raise $60 million. By late March, however, the company had elected to lock in the first $45 million, due to the upheaval caused

Acepodia is using its antibody-cell conjugation platform to link tumor-targeting antibodies to the surface of cell therapies while avoiding genetic engineering. The platform, which has the potential for cost savings compared with CAR T therapy, led JW Therapeutics to partner with the company for commercialization of its lead program Tuesday.

Recce Pharmaceuticals Ltd., which is developing a new class of broad-spectrum synthetic antibiotics, announced positive data showing significant in-vivo antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) in rats with topical burns treated with its lead compound RECCE 327.

Biotech firm CalciMedica announced Thursday its anti-inflammatory drug Auxora is showing promise in treating COVID-19 when combined with standard care, reducing ventilator use by half and speeding recovery.

Technology Networks spoke with James Graham, Executive Director at Recce Pharmaceuticals, to learn more about how synthetic antibiotics differ from those derived from natural sources. He also discusses how the company has developed a novel class of synthetic antibiotics and elaborates on their mechanism of action.

Sotio is developing an IL-15 superagonist, SO-C101, as a potent immunotherapy for patients with cancer. This study examined SO-C101 in multiple tumor mouse models alone and in combination with PD-1 inhibition.